Overview

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Status:
Withdrawn
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
Otsuka America Pharmaceutical
Treatments:
Aripiprazole